Effectiveness of mRNA COVID-19 Monovalent and Bivalent Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario, Canada: A Canadian Immunization Research Network Study

Thumbnail
Name:
jiad419.pdf
Size:
383.2Kb
Format:
PDF
Download
Cast your vote
 
Your vote was cast
Thank you for your feedback
Author
Grewal, Ramandip
Buchan, Sarah A
Nguyen, Lena
Nasreen, Sharifa
Austin, Peter C
Brown, Kevin A
Gubbay, Jonathan
Lee, Nelson
Schwartz, Kevin L
Tadrous, Mina
Keyword
COVID-19
omicron
bivalent
mRNA
vaccine effectiveness
Journal title
The Journal of Infectious Diseases
Date Published
2023-10-05
Publication Volume
229
Publication Issue
2
Publication Begin page
394
Publication End page
397

Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12648/14975
Abstract
We estimated the effectiveness of booster doses of monovalent and bivalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults aged ≥50 years in Ontario, Canada. Monovalent and bivalent mRNA COVID-19 booster doses provided similar strong initial protection against severe outcomes. Uncertainty remains around waning of protection from these vaccines.
Citation
Grewal R, Buchan SA, Nguyen L, Nasreen S, Austin PC, Brown KA, Gubbay J, Lee N, Schwartz KL, Tadrous M, Wilson K, Wilson SE, Kwong JC. Effectiveness of mRNA COVID-19 Monovalent and Bivalent Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario, Canada: A Canadian Immunization Research Network Study. J Infect Dis. 2024 Feb 14;229(2):394-397. doi: 10.1093/infdis/jiad419. PMID: 37798119; PMCID: PMC10873169.
DOI
10.1093/infdis/jiad419
Collections
https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/